Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines.

Eadie LN, Hughes TP, White DL.

PLoS One. 2016 Aug 18;11(8):e0161470. doi: 10.1371/journal.pone.0161470. eCollection 2016.

2.

Subtle Dynamic Changes Accompany Hck Activation by HIV-1 Nef and are Reversed by an Antiretroviral Kinase Inhibitor.

Wales TE, Hochrein JM, Morgan CR, Emert-Sedlak LA, Smithgall TE, Engen JR.

Biochemistry. 2015 Oct 20;54(41):6382-91. doi: 10.1021/acs.biochem.5b00875. Epub 2015 Oct 6.

PMID:
26440750
3.

Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Function.

Grover P, Shi H, Baumgartner M, Camacho CJ, Smithgall TE.

PLoS One. 2015 Jul 29;10(7):e0133590. doi: 10.1371/journal.pone.0133590. eCollection 2015.

4.

DNA mismatch repair gene MLH1 induces apoptosis in prostate cancer cells.

Fukuhara S, Chang I, Mitsui Y, Chiyomaru T, Yamamura S, Majid S, Saini S, Hirata H, Deng G, Gill A, Wong DK, Shiina H, Nonomura N, Dahiya R, Tanaka Y.

Oncotarget. 2014 Nov 30;5(22):11297-307.

5.

Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin.

Obr A, Röselová P, Grebeňová D, Kuželová K.

PLoS One. 2014 Sep 8;9(9):e107367. doi: 10.1371/journal.pone.0107367. eCollection 2014.

7.

Partial cooperative unfolding in proteins as observed by hydrogen exchange mass spectrometry.

Engen JR, Wales TE, Chen S, Marzluff EM, Hassell KM, Weis DD, Smithgall TE.

Int Rev Phys Chem. 2013 Jan 1;32(1):96-127.

8.

Structure and dynamic regulation of Abl kinases.

Panjarian S, Iacob RE, Chen S, Engen JR, Smithgall TE.

J Biol Chem. 2013 Feb 22;288(8):5443-50. doi: 10.1074/jbc.R112.438382. Epub 2013 Jan 11. Review.

9.

Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors.

Panjarian S, Iacob RE, Chen S, Wales TE, Engen JR, Smithgall TE.

J Biol Chem. 2013 Mar 1;288(9):6116-29. doi: 10.1074/jbc.M112.431312. Epub 2013 Jan 9.

10.

Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.

Singh MM, Howard A, Irwin ME, Gao Y, Lu X, Multani A, Chandra J.

PLoS One. 2012;7(12):e51611. doi: 10.1371/journal.pone.0051611. Epub 2012 Dec 17.

11.

Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.

Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R.

Cancer Biol Ther. 2012 Nov;13(13):1244-54. doi: 10.4161/cbt.21460. Epub 2012 Aug 16.

12.

Functions of the Lyn tyrosine kinase in health and disease.

Ingley E.

Cell Commun Signal. 2012 Jul 17;10(1):21. doi: 10.1186/1478-811X-10-21.

13.

Functional mechanisms and roles of adaptor proteins in abl-regulated cytoskeletal actin dynamics.

Sato M, Maruoka M, Takeya T.

J Signal Transduct. 2012;2012:414913. doi: 10.1155/2012/414913. Epub 2012 May 17.

14.

SH3 domain tyrosine phosphorylation--sites, role and evolution.

Tatárová Z, Brábek J, Rösel D, Novotný M.

PLoS One. 2012;7(5):e36310. doi: 10.1371/journal.pone.0036310. Epub 2012 May 15.

15.

Tyrosine phosphorylation within the SH3 domain regulates CAS subcellular localization, cell migration, and invasiveness.

Janoštiak R, Tolde O, Brůhová Z, Novotný M, Hanks SK, Rösel D, Brábek J.

Mol Biol Cell. 2011 Nov;22(22):4256-67. doi: 10.1091/mbc.E11-03-0207. Epub 2011 Sep 21.

16.

Inhibition of protein-tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl protein.

Alvira D, Naughton R, Bhatt L, Tedesco S, Landry WD, Cotter TG.

J Biol Chem. 2011 Sep 16;286(37):32313-23. doi: 10.1074/jbc.M111.249060. Epub 2011 Jul 27.

17.

ABL tyrosine kinases: evolution of function, regulation, and specificity.

Colicelli J.

Sci Signal. 2010 Sep 14;3(139):re6. doi: 10.1126/scisignal.3139re6. Review. Erratum in: Sci Signal. 2011 Aug 30;4(188):er4.

18.

Targeted therapy of chronic myeloid leukemia.

Sullivan C, Peng C, Chen Y, Li D, Li S.

Biochem Pharmacol. 2010 Sep 1;80(5):584-91. doi: 10.1016/j.bcp.2010.05.001. Epub 2010 May 12. Review.

19.

Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Pene-Dumitrescu T, Smithgall TE.

J Biol Chem. 2010 Jul 9;285(28):21446-57. doi: 10.1074/jbc.M109.090043. Epub 2010 May 7.

20.

DHHC20: a human palmitoyl acyltransferase that causes cellular transformation.

Draper JM, Smith CD.

Mol Membr Biol. 2010 Apr;27(2-3):123-36. doi: 10.3109/09687681003616854.

Items per page

Supplemental Content

Write to the Help Desk